CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has signed an initial two-year agreement with the French national blood service, Etablissement Français du Sang (EFS), for the INTERCEPT Blood System for platelets. The terms of the agreement provide for INTERCEPT equipment and disposable purchases of up to $8.0 million, with the actual amounts determined by the rate of implementation in EFS regional centers.
